[go: up one dir, main page]

CZ20003672A3 - Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu - Google Patents

Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu Download PDF

Info

Publication number
CZ20003672A3
CZ20003672A3 CZ20003672A CZ20003672A CZ20003672A3 CZ 20003672 A3 CZ20003672 A3 CZ 20003672A3 CZ 20003672 A CZ20003672 A CZ 20003672A CZ 20003672 A CZ20003672 A CZ 20003672A CZ 20003672 A3 CZ20003672 A3 CZ 20003672A3
Authority
CZ
Czechia
Prior art keywords
aryl
group
alkyl
product
hydroxy
Prior art date
Application number
CZ20003672A
Other languages
Czech (cs)
English (en)
Inventor
Nizal Samuel Chandrakumar
Bipinchandra Nanubhai Desai
Balekudru Devadas
Renne Huff
Ish K. Khanna
Shashidhar N. Rao
Joseph G. Rico
Thomas E. Rogers
Peter G. Ruminski
Mark Andrew Russell
Yi Yu
Alan Frank Gasiecki
James W. Malecha
Julie M. Miyashiro
Original Assignee
G. D. Searle & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G. D. Searle & Co. filed Critical G. D. Searle & Co.
Publication of CZ20003672A3 publication Critical patent/CZ20003672A3/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CZ20003672A 1998-04-10 1999-04-09 Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu CZ20003672A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8139498P 1998-04-10 1998-04-10

Publications (1)

Publication Number Publication Date
CZ20003672A3 true CZ20003672A3 (cs) 2001-08-15

Family

ID=22163868

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20003672A CZ20003672A3 (cs) 1998-04-10 1999-04-09 Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu

Country Status (17)

Country Link
EP (1) EP1070060A1 (fr)
JP (1) JP2002511462A (fr)
KR (1) KR20010042614A (fr)
CN (1) CN1304406A (fr)
AR (1) AR015759A1 (fr)
AU (1) AU765294B2 (fr)
BR (1) BR9910119A (fr)
CA (1) CA2326665A1 (fr)
CZ (1) CZ20003672A3 (fr)
IL (1) IL138677A0 (fr)
MY (1) MY133473A (fr)
NO (1) NO20005084L (fr)
NZ (1) NZ507292A (fr)
PL (1) PL343406A1 (fr)
RU (1) RU2215746C2 (fr)
TW (1) TWI247008B (fr)
WO (1) WO1999052896A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172256B1 (en) * 1998-03-04 2001-01-09 G.D. Searle & Co. Chiral-β-amino acid compounds and derivatives thereof
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
JP2002533404A (ja) * 1998-12-23 2002-10-08 ジー・ディー・サール・アンド・カンパニー 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法
AU760174B2 (en) 1999-02-09 2003-05-08 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
NZ514602A (en) 1999-04-12 2003-06-30 Aventis Pharma Ltd Substituted bicyclic heteroaryl compounds as integrin antagonists
GB9908355D0 (en) * 1999-04-12 1999-06-09 Rhone Poulenc Rorer Ltd Chemical compounds
CA2371604A1 (fr) * 1999-04-28 2000-11-09 Basf Aktiengesellschaft Antagonistes recepteurs d'integrine
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
JP2003531141A (ja) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド エナミン誘導体
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6720315B2 (en) 2000-06-15 2004-04-13 Pharmacia Corporation Dihydrostilbene alkanoic acid derivatives
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
DE10204789A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
AU2003299600A1 (en) * 2002-12-20 2004-07-29 Pharmacia Corpration The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EA201000612A1 (ru) 2007-10-18 2010-10-29 Бёрингер Ингельхайм Интернациональ Гмбх Антагонисты cgrp-пептиды
EP2065381A1 (fr) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes du CGRP
US20120149698A1 (en) * 2007-11-22 2012-06-14 Boehringer Ingelheim International Gmbh Nouvel compounds
EP2225223B1 (fr) 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Composés organiques
MX2015000794A (es) 2012-07-18 2015-10-12 Univ Saint Louis Derivados de aminoácido beta como antagonistas de integrina.
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
JP6649902B2 (ja) 2014-05-30 2020-02-19 ファイザー・インク 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体
RU2729518C2 (ru) 2015-12-30 2020-08-07 Сент-Луис Юниверсити Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина
JP7220653B2 (ja) * 2016-11-08 2023-02-10 ブリストル-マイヤーズ スクイブ カンパニー アルファvインテグリン阻害剤としてのピロールアミド
JP7661969B2 (ja) * 2020-05-14 2025-04-15 Ube株式会社 1,4,5,6-テトラヒドロピリミジン-2-アミン誘導体
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes
EP4431098A4 (fr) 2021-11-12 2025-10-08 Ube Corp Composition pharmaceutique pour le traitement ou la prévention du syndrome de l'alport
CN115626912B (zh) * 2022-09-27 2024-03-26 中山大学 一种硫脲化合物及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120859A (en) * 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
FR2676054B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
RU2126001C1 (ru) * 1995-01-10 1999-02-10 Самдзин Фармасьютикал Ко., Лтд Производные пиперазина и фармацевтическая композиция на их основе
NZ318926A (en) * 1995-08-30 1999-04-29 Searle & Co Alpha v beta 3 integrin (vitronectin) inhibitors or anatagonists derived from benzoic acid for treating diseases of cell adhesion
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
CA2263999A1 (fr) * 1996-08-29 1998-03-05 Merck & Co., Inc. Antagonistes de l'integrine

Also Published As

Publication number Publication date
MY133473A (en) 2007-11-30
JP2002511462A (ja) 2002-04-16
NO20005084D0 (no) 2000-10-09
EP1070060A1 (fr) 2001-01-24
NO20005084L (no) 2000-11-27
IL138677A0 (en) 2001-10-31
BR9910119A (pt) 2001-10-09
WO1999052896A1 (fr) 1999-10-21
CN1304406A (zh) 2001-07-18
PL343406A1 (en) 2001-08-13
TWI247008B (en) 2006-01-11
AU3449999A (en) 1999-11-01
KR20010042614A (ko) 2001-05-25
AU765294B2 (en) 2003-09-11
AR015759A1 (es) 2001-05-16
CA2326665A1 (fr) 1999-10-21
NZ507292A (en) 2003-12-19
RU2215746C2 (ru) 2003-11-10

Similar Documents

Publication Publication Date Title
CZ20003672A3 (cs) Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu
US5773644A (en) Cyclopropyl alkanoic acid derivatives
DE69705829T2 (de) Meta-substituierte phenylsulphonamidderivate
AU702487B2 (en) Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
AP1244A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists.
JP2000510098A (ja) 桂皮酸誘導体
JPH0899962A (ja) 4−アミノキナゾリン誘導体、その製造方法およびそれを含有する医薬品
US6013651A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof
US6689754B1 (en) Heterocyclic glycyl β-alanine derivatives
US20020072500A1 (en) Hydroxy acid integrin antagonists
MX2008015979A (es) Derivados de aril- y heteroaril-etil-acilguanidina, su preparacion y su aplicacion en terapeutica.
US6720327B2 (en) Lactone integrin antagonists
MXPA00009967A (en) Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
JP2004503540A (ja) インテグリンアンタゴニストとして有用なジヒドロスチルベンアルカン酸誘導体
US20040019206A1 (en) Lactone integrin antagonists
CZ20003218A3 (cs) Deriváty meta-azacyklické aminobenzoové kyseliny a jejich deriváty, které jsou antagonisty integrinu